Colorectal adenocarcinoma
MONDO:0005008The most common type of colorectal carcinoma. It is characterized by the presence of malignant glandular epithelial cells invading through the muscularis mucosa into the submucosa. Histologic variants include mucinous adenocarcinoma, signet ring cell carcinoma, medullary carcinoma, serrated adenocarcinoma, cribriform comedo-type adenocarcinoma, and micropapillary adenocarcinoma.
Also known as: adenocarcinoma of large bowel, adenocarcinoma of large intestine, adenocarcinoma of the large bowel, adenocarcinoma of the large intestine, colorectal (colon or rectal) adenocarcinoma, colorectal adenocarcinoma, colorectum adenocarcinoma, large bowel adenocarcinoma
3425 clinical trials for this condition and its sub-types, 247 tagged with Colorectal adenocarcinoma itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Colorectal adenocarcinoma
-
Rectum adenocarcinoma 232 trials · 233 incl. sub-types
4 sub-types
- Anus adenocarcinoma 0 trials · 1 incl. sub-types Sub-types →
- Rectal signet ring cell adenocarcinoma 1 trial
- Rectum mucinous adenocarcinoma 1 trial Sub-types →
- Rectal medullary carcinoma 0 trials
-
Colon adenocarcinoma 90 trials · 121 incl. sub-types
5 sub-types
- Cecum adenocarcinoma 0 trials · 31 incl. sub-types Sub-types →
- Colon mucinous adenocarcinoma 2 trials · 21 incl. sub-types Sub-types →
- Colon signet ring cell adenocarcinoma 2 trials
- Colon medullary carcinoma 0 trials
- Submucosal invasive colon adenocarcinoma 0 trials
-
Colorectal signet ring cell carcinoma 0 trials · 3 incl. sub-types
2 sub-types
-
Colorectal medullary carcinoma 0 trials
2 sub-types
- Colon medullary carcinoma 0 trials
- Rectal medullary carcinoma 0 trials
Most studied deeper sub-types
-
Can a Drug-Radiation combo outsmart Treatment-Resistant colorectal cancer?
Disease control CancelledThis phase 2 trial is testing whether combining an experimental drug called S-531011 with a precise radiation technique known as RadScopal can help control metastatic colorectal cancer that has not responded to prior treatments. The study enrolls about 30 adults with advanced dis…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New hope for Hard-to-Treat colorectal cancer: immunotherapy combo under trial
Disease control OngoingThis phase III trial compares two first-line treatments for people with a specific genetic subtype of metastatic colorectal cancer (dMMR/MSI-H). One group receives the immunotherapy drug atezolizumab alone, while the other gets atezolizumab combined with chemotherapy (FOLFOX) and…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New cocktail aims to outsmart resistant colorectal cancer
Disease control OngoingThis early-phase trial is testing a combination of chemotherapy (FOLFOX), an anti-angiogenic drug (bevacizumab), and two immunotherapies (botensilimab and balstilimab) in 20 patients with MSS metastatic colorectal cancer, a type that usually doesn't respond to immunotherapy. The …
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for tough colon cancer: Triple-Drug attack shows promise
Disease control OngoingThis study tests a combination of three drugs (botensilimab, balstilimab, and regorafenib) in people with a type of advanced colorectal cancer that is hard to treat (MSS type) and has worsened after standard chemotherapy. The goal is to see if this mix can shrink tumors or slow t…
Phase 1/2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Could a simple injection before and after surgery keep colorectal cancer at bay?
Disease control OngoingThis study tests whether a drug called QBECO, given as a self-injection before and after liver surgery, can lower the chance of colorectal cancer coming back or spreading. About 115 adults with colorectal cancer that has spread to the liver will take part. They will inject the dr…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Aug 23, 2026 00:00 UTC
-
New combo aims to wipe out hidden cancer cells after chemo
Disease control OngoingThis study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will r…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for tough colorectal cancer: drug combo shows promise
Disease control OngoingThis study tests two drugs, panitumumab and trametinib, in people with stage IV colorectal cancer that no longer responds to standard treatments. The goal is to see if these drugs can shrink tumors or slow cancer growth. About 59 participants will receive either panitumumab alone…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Adding a Blood-Vessel blocker to maintenance chemo may extend control of advanced colorectal cancer
Disease control OngoingThis phase 3 trial tests whether adding bevacizumab (a drug that starves tumors by blocking new blood vessels) to standard maintenance chemotherapy helps people with metastatic colorectal cancer stay progression-free longer. About 400 adults whose disease is controlled after 4–6 …
Phase 3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New combo approach for Lung-Limited colorectal cancer shows promise in early trial
Disease control OngoingThis phase 2 trial studies whether combining chemotherapy with surgery to remove lung tumors works better than either treatment alone for patients with colorectal cancer that has spread only to the lungs. About 40 participants will be grouped by risk level to see if the combinati…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat colorectal tumors
Disease control By invitation onlyThis clinical trial is testing whether combining two drugs—capecitabine (a chemotherapy pill) and lenvatinib (a targeted therapy)—can shrink tumors in people with advanced colorectal cancer that has stopped responding to standard treatments. The study enrolls adults aged 19 and o…
Phase 1/2 • Sponsor: Seoul National University Bundang Hospital • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control By invitation onlyThis early-stage trial is testing a personalized peptide vaccine for people with advanced pancreatic or colorectal cancer that has spread. The vaccine is made from each patient's own tumor cells and blood, aiming to train the immune system to attack the cancer. The study will che…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Poop pills plus immunotherapy: new hope for colorectal cancer patients?
Disease control OngoingThis pilot trial tests whether giving fecal microbiota transplants (FMT) along with re-introducing anti-PD-1 immunotherapy (pembrolizumab or nivolumab) can help control metastatic colorectal cancer in patients who previously did not respond to immunotherapy alone. The study enrol…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Liver-Directed chemo may shrink tumors enough for surgery in colorectal cancer
Disease control OngoingThis phase II trial tests whether delivering chemotherapy directly into the liver (hepatic arterial infusion) along with standard IV chemo can shrink inoperable liver tumors from colorectal cancer enough to allow surgical removal. The study involves 64 participants whose cancer h…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo therapy targets tough colorectal cancer
Disease control PausedThis study tests the safety and effectiveness of combining the experimental drug AVUTOMETINIB (VS-6766) with cetuximab in people with advanced colorectal cancer that has a KRAS mutation. It is for those whose cancer worsened after prior treatments or who cannot tolerate them. The…
Phase 1/2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New combo treatment may slow colorectal cancer spread
Disease control OngoingThis trial is for people with colorectal cancer that has spread to a few spots in the body but cannot be fully removed by surgery alone. After 3-4 months of standard chemotherapy, participants either continue chemotherapy alone or also receive local ablative therapy—such as surge…
Sponsor: Australasian Gastro-Intestinal Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Fewer cuts, same hope: new surgery for colon cancer tested
Disease control OngoingThis study compares a newer, less invasive surgery (reduced-port laparoscopy) to standard laparoscopic surgery for people with colon or upper rectal cancer. The goal is to see if the newer approach is as safe and effective, while possibly causing less pain and faster recovery. 50…
Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to stop colorectal cancer from coming back
Disease control By invitation onlyThis early-phase trial tests whether adding a personalized immune treatment to standard chemotherapy can prevent cancer recurrence in colorectal cancer patients who have minimal residual disease (MRD) after surgery. Ten adults aged 18-80 with stage II (high-risk) or stage III col…
Early phase 1 • Sponsor: Second Affiliated Hospital of Wenzhou Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug aims to shrink hard-to-treat GI tumors
Disease control OngoingThis study tests a new medicine called raludotatug deruxtecan in about 160 adults with advanced gastrointestinal cancers (pancreatic, bile duct, gallbladder, colorectal, stomach, or gastroesophageal junction). The drug is designed to attach to cancer cells and deliver a treatment…
Phase 2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Could a lower dose of immunotherapy shrink colorectal tumors before surgery?
Disease control OngoingThis phase 2 trial is testing whether low doses of the immunotherapy drugs nivolumab or pembrolizumab can shrink tumors in people with a specific genetic type of colorectal cancer (MSI/dMMR) before they have surgery. The study involves 30 participants with stage II-III disease wh…
Phase 2 • Sponsor: Blokhin's Russian Cancer Research Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Gut bacteria boost? new trial tests probiotics to help immunotherapy fight stubborn colorectal cancer
Disease control OngoingThis early-phase study tests whether adding Akkermansia probiotics to standard immunotherapy and chemotherapy can safely help patients with advanced colorectal cancer that hasn't responded to prior treatments. The trial enrolls 22 adults whose tumors are MSS/pMMR type, which typi…
Sponsor: West China Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New combo shows promise for Hard-to-Treat colorectal cancer
Disease control OngoingThis phase 2 trial is testing a combination of two drugs, cabozantinib and nivolumab, in 48 people with advanced colorectal cancer that has not responded to standard treatments. The goal is to see if the combination can shrink or stabilize tumors. All participants have a type of …
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Could chemo around surgery beat cancer spread in the belly?
Disease control OngoingThis study tests whether giving chemotherapy before and after surgery (plus heated chemo directly into the abdomen) helps people with colorectal cancer that has spread to the lining of the abdomen live longer. About 358 adults with resectable disease are randomly assigned to eith…
Phase 2/3 • Sponsor: Koen Rovers • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Could vitamin D3 boost chemo for advanced colon cancer?
Disease control OngoingThis phase III trial tests whether adding high-dose vitamin D3 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer. About 455 patients who have not had prior treatment for their advanced disease are taking part. The goal is to see if the vitami…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New combo shows promise for Tough-to-Treat colorectal cancer
Disease control OngoingThis phase 3 trial tests whether adding the immunotherapy drug sintilimab to standard chemotherapy and bevacizumab helps people with a specific type of advanced colorectal cancer (RAS-mutant, MSS) live longer without their cancer growing. About 446 adults who have not had prior t…
Phase 3 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Last-Resort cancer drug made available to patients with no alternatives
Disease control Expanded access (ended)This expanded access program offers fruquintinib, a targeted cancer drug, to adults with metastatic colorectal cancer that has worsened after all standard treatments. Participants take the drug as a capsule daily for three weeks, then one week off. The goal is to provide access u…
Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo aims to outsmart stubborn colorectal cancer
Disease control OngoingThis phase 2 trial tests whether combining the immunotherapy nivolumab (Opdivo) with the chemotherapy oxaliplatin can help control or shrink metastatic colorectal cancer that is mismatch repair proficient (pMMR) or microsatellite stable (MSS)—types that usually don't respond well…
Phase 2 • Sponsor: University Hospital, Akershus • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new drug called KFA115, either by itself or combined with the immunotherapy Keytruda (pembrolizumab), in 126 people with advanced cancers like lung, skin, kidney, and others. The main goal is to check safety and find the best dose. It is not ye…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
New antibody TST003 takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing a new drug called TST003 in about 111 people with advanced solid tumors (cancers that have spread or cannot be removed by surgery). TST003 is an antibody that blocks a protein called GREM1, which may help tumors grow. The main goals are to find a…
Phase 1/2 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Immunotherapy combo shows promise against tough colorectal cancer
Disease control OngoingThis Phase 2 trial tests two immunotherapy drugs (iparomlimab and tuvonralimab) given before surgery to 29 patients with a specific genetic type of colorectal cancer (MSI-H/dMMR). The goal is to see if this combination can completely eliminate the tumor before surgery. Researcher…
Phase 2 • Sponsor: Sir Run Run Shaw Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New hope for advanced colorectal cancer: experimental combo shows promise
Disease control OngoingThis study tests a new drug (HR070803) added to standard chemotherapy and a targeted therapy for people with advanced colorectal cancer that has spread and cannot be removed by surgery. About 669 participants will receive either the new combo or standard treatment. The goal is to…
Phase 2/3 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Promising cancer drug trial pulled before it even started
Disease control CancelledThis was a planned Phase 2 trial to test the drug CBX-12 in people with advanced colorectal cancer that had stopped responding to standard treatments. The drug was designed to deliver a cancer-killing substance directly to tumor cells. However, the study was withdrawn before any …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Triple-Drug cocktail targets Hard-to-Treat colorectal cancer
Disease control OngoingThis study tests a combination of three drugs (tiragolumab, atezolizumab, and bevacizumab) in people with a type of advanced colorectal cancer that has not responded to prior treatments. The goal is to see if the combo can shrink tumors or slow the disease. Participants receive t…
Phase 2 • Sponsor: University of Colorado, Denver • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
New hope for Tough-to-Treat colorectal cancer?
Disease control OngoingThis study tests a new drug called nelmastobart combined with the chemotherapy capecitabine in people with metastatic colorectal cancer that no longer responds to standard treatments. About 59 adults will receive the combination to see if it is safe and can slow cancer growth. Th…
Phase 1/2 • Sponsor: Korea University Anam Hospital • Aim: Disease control
Last updated Jun 26, 2026 14:25 UTC
-
New drug combo aims to shrink Hard-to-Treat colorectal tumors
Disease control OngoingThis phase 2 trial tests two experimental immunotherapy drugs, botensilimab and balstilimab, alone or together, against standard chemotherapy in 234 people with metastatic colorectal cancer that has not responded to prior treatments. The goal is to see if these drugs can shrink t…
Phase 2 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:18 UTC
-
Blood test may spot hidden cancer after abdominal surgery
Diagnosis OngoingThis study looks at whether a blood test can detect if cancer comes back after surgery for colorectal or appendix cancer that spread to the abdomen. Researchers will collect blood samples from 55 patients before and after surgery to measure DNA changes. The goal is to see if this…
Sponsor: University of Chicago • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
Can a vaccine stop GI cancers from returning?
Prevention PausedResearchers are testing an experimental vaccine called Ad5.F35-hGCC-PADRE in adults who have had surgery and standard treatment for gastrointestinal cancers, including pancreatic, colorectal, esophageal, gastric, and small bowel adenocarcinomas. The trial aims to find a safe dose…
Phase 2 • Sponsor: Thomas Jefferson University • Aim: Prevention
Last updated Sep 16, 2026 00:00 UTC
-
Pre-Surgery video may calm nerves and boost understanding in colorectal cancer patients
Symptom relief By invitation onlyThis trial tests whether watching an educational video before a surgical consultation helps colorectal cancer patients feel less anxious and more informed. About 100 adults scheduled for curative-intent colon or rectal surgery will be randomly assigned to either watch the video b…
Sponsor: University Health Network, Toronto • Aim: Symptom relief
Last updated Jul 09, 2026 00:00 UTC
-
New study aims to unlock secrets of colorectal cancer in young people
Knowledge-focused OngoingThis study collects blood, tissue, and stool samples from 160 people aged 18-49, including those with young onset colorectal cancer and healthy volunteers. Researchers will analyze the samples to create a database that helps explain why colorectal cancer is rising in younger adul…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 22, 2026 00:00 UTC
-
Blood test could decide who needs stronger or milder chemo for colorectal cancer
Knowledge-focused OngoingThis study is testing whether a blood test that looks for tumor DNA (ctDNA) can help doctors choose the right amount of chemotherapy for people with stage III colorectal cancer. About 2,450 participants will be split into groups based on their ctDNA results: those with negative c…
Phase 3 • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Can your genes predict chemo nerve pain?
Knowledge-focused OngoingThis study looks at how a person's genes and medical history might help predict nerve damage caused by chemotherapy. Researchers will follow 300 people with certain cancers who are scheduled for specific chemo drugs. The goal is to find patterns that could help prevent or reduce …
Sponsor: National Cheng-Kung University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
Global study reviews brain metastasis treatments in colorectal cancer patients
Knowledge-focused OngoingThis observational study looks back at 700 patients from 15 hospitals in 2 countries to compare local treatments like surgery and radiation for brain metastases that spread from colorectal cancer. Researchers will track how long patients live and how long it takes for brain tumor…
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can new blood and imaging tests predict colon cancer liver spread?
Knowledge-focused OngoingThis pilot study aims to develop new ways to diagnose colon cancer and predict if it will spread to the liver. Researchers will collect blood and liver tissue samples from 51 patients undergoing surgery for colon cancer or benign colon growths. The goal is to find biomarkers that…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC